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Abstract
Background: Staging of B-cell non Hodgkin’s lymphoma (NHL) routinely involves bone marrow (BM) examination
by trephine biopsy (BM-TB). The evidence of disease in the BM-TB results in a clinical stage IV classification
affecting therapeutic strategies for NHL patients. BM immunophenotyping by flow cytometry (FC) is also used,
although its clinical value is still under debate.
Methods: Using FC we analyzed 1,000 paired BM aspirates and peripheral blood (PB) samples from 591 NHL
patients to investigate the concordance between BM and PB. B-lymphocytes were defined monoclonal when a
ratio of 0.3 < /l > 3 was observed. Aberrant immunophenotypes present in the B-cell subpopulation were also
investigated. BM-TB was also performed in 84.1% of samples (841/1000), and concordance between BM-TB and
BM-FC was evaluated. Concordance was defined as the presence of a positive (in terms of disease detection) or
negative result in both BM-FC and PB-FC or BM-TB and BM-FC.
Results: Using FC, the overall concordance between BM and PB was 95%. Among the discordant cases (ie presence
of neoplastic B-lymphocyte in the BM but under the sensibility of the technique in the PB) the most frequent
diagnosis was Waldenstrom’s macroglobulinemia (WM, accounting for 20.8% of all discordant cases). The expression
of CXCR4, a receptor involved in B-cell trafficking and homing, was found to be down regulated in WM compared to
other NHL types, thus suggesting a possible role of CXCR4 in WM cell homing in the BM. WM excluded, FC
investigation of BM and PB in NHL patients gives overlapping information.
BM involvement was observed by FC in 38% of samples, and concordance between BM-FC and BM-TB was 85%.
Conclusions: The finding that FC data from BM and PB samples overlap in NHL might have major implications for
the design of future clinical studies and for patients’ follow-up.
Background
Bone marrow (BM) examination by trephine biopsy
(BM-TB) is routinely performed during staging and fol-
low-up of patients affected by B-cell non-Hodgkin lym-
phoma (NHL). BM disease results in a stage IV
classification, and may affect therapeutic strategies [1].
Flow cytometry BM immunophenotyping (BM-FC) is
used in adjunct to BM-TB, even though its clinical value
is still under investigation [2]. In the present study, in
addition to the BM aspirate, the peripheral blood (PB)
was analyzed to investigate if malignant cells were
restricted to BM or circulating in the blood.
Chemokine receptors are expressed by a variety of
cells, including lymphoid cells, and mediate cell traffick-
ing and homing. These receptors may also be involved
in the migration and dissemination of NHL cells [3].
The stromal derived factor -1 (SDF-1, CXCL12) chemo-
kine plays a crucial role in the retention of a variety of
cells into BM niches through its receptor CXCR4 [3,4].
We investigated CXCR4 in different NHL subtypes to
assess whether its expression correlates with differences
in the frequency of NHL cells in the PB versus the BM.
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Methods
We retrospectively analyzed 1,000 paired BM aspirates
and PB samples from 591 NHL patients (i.e. 1000 BM
samples along with 1000 PB samples from the same
day) consecutively collected in our Institute from 2000
to 2007. BM-TB was also performed in 84.1% of paired
samples (841/1000), and, as BM-TB is considered the
“gold-standard” for NHL staging and follow up, we also
evaluated concordance between BM-TB and BM-FC.
Among the 1000 consecutive paired samples, 31%
were collected at the time of first diagnosis (616/2000),
and 69% after therapy. For all patients, the diagnosis of
NHL was obtained by morphology, phenotype and
molecular analysis of nodal or extra-nodal sites and
established according to the World Health Organization
recommendations [5]. Hairy Cell Leukaemia, T-cell
NHL, Hodgkin disease and multiple myeloma patients
were not included in this study. The different subtypes
of B-cell NHL are described in Table 1.
Four- (or, after 2005, six-) colour multiparametric FC
was performed (Figure 1). Monoclonal antibodies
including anti-CD45, -CD19, -CD20, surface IgM,
-CD10, -CD5, -CD43, -CD23, anti- and anti -l Ig light
chain were used to analyze the B-lymphocyte immuno-
phenotype. When light chain restriction was observed,
anti-CD38, FMC-7, CD79b, CD22, CD103, CD11c,
CD25 expression were also investigated on B-cells to
better characterize B-cell phenotype [6] and to investi-
gate the concordance between the diagnosis reported
and the phenotype of the pathological B-lymphocytes
observed. To detect light chain restriction, we used anti-
FITC/anti -l Pe/CD45 PerCP/CD19 APC or anti-
FITC/anti -l Pe/CD45 PerCP/CD10 Pe-Cy-7/CD5 APC/
CD19 APC-Cy-7. As CD19-APC-Cy7 shows a very low
signal-to-noise ratio in some cases like FL/DLBCL with
low level CD19, the combination CD19 Pe/CD45 PerCP
was used to compare the percentage of CD19 positive
cells obtained with both markers. B-lymphocytes were
defined monoclonal when a ratio of 0.3 < /l > 3 was
observed [7] or, for some lymphocytic lymphoma/
chronic lymphocytic leukaemia (CLL) patients, when
surface membrane light chains were absent. At least
100 CD19+ events showing the expected immunophe-
notype were required to define a FC test as positive [8].
In addition to this panel, anti-CD3, -CD4, -CD8 and
-CD16+56 were routinely analyzed to gain information
regarding the distribution of lymphocyte sub-popula-
tions. Controls included substitution of the relevant
monoclonal antibody by a murine Ig of the same iso-
type. Monoclonal antibodies were purchased from BD
Biosciences (Mountain View, CA), and used at the
recommended concentration.
We also evaluated CXCR4 expression on B-cells in 54
paired BM-aspirates and PB (10 WM, 14 DLBC, 18 FL
and 12 CLL).
For CXCR4 detection, 10 μl of PE-conjugated anti
CXCR4 (BD, clone 12g5) was used in combination
with anti CD45 Per-CP and CD19 Pe-Cy7. An isotype-
matched negative control was used. Mean fluorescence
intensity (MFI) ratios were calculated by dividing the
MFI for CXCR4 by the MFI of the respective isotype-
matched negative control, both in the BM aspirates
and in PB. For sample preparation, a stain - lyse and
wash standard procedure was used. Red cells were
lysed by a NH4Cl solution. Measurements were per-
formed on a FACS-Calibur or FACS-Canto (BD Bio-
sciences), equipped with a second laser. Acquisition
was stopped after collection of more than 200.000 total
events or when at least 100 CD19 positive events were
collected. Sensitivity of the procedure was established
by serial dilution experiments as 1/10,000.
BM-TB were fixed in 10% buffered formalin, decalci-
fied with EDTA, embedded in paraffin and stained with
haematoxylin-eosin. Immunohistochemistry with anti
CD3-, CD5, CD10, CD20, CD23, CD34, CD43, CD79a,
bcl-2, bcl-6, cyclin D1, Ki-67 was performed to distin-
guish between reactive and neoplastic lymphoid infiltra-
tion and to differentiate the different subtypes.
Table 1 Patient’s Characteristics
Diagnosis Number of Patients % of Patients
Follicular Lymphoma
(FL)
205 35%
Diffuse Large B cell Lymphoma
(DLBC-L)
142 24%
Mantle Cell Lymphoma
(MCL)
47 8%
Marginal Zone Lymphoma - Mucose Associated Lymphoma Tissue
(MZL-MALT)
74 13%
Lymphocytic lymphoma/chronic lymphocytic leukemia (CLL) 83 14%
Waldenstrom’s macroglobulinemia (WM) 40 7%
TOTAL 591 100%
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Concordance was defined as the presence of a positive
(in terms of disease detection) or negative result in both
BM-FC and PB-FC or BM-TB and BM-FC. Statistical
comparisons were performed using the t-test, analysis of
variance (ANOVA) and linear regression when data
were normally distributed and the non-parametric ana-
lyses of Spearman and Mann-Whitney when data were
not normally distributed. Values of p lower than 0.05
were considered as significant.
Results
Concordance between BM-FC and PB-FC
As shown in Table 2, the most frequent diagnoses were
Follicular NHL (FL, 35%) and Diffuse Large B-Cell NHL
(DLBC, 24%). The overall FC concordance between BM
and PB was 95.2% (Table 2) in all NHL subtypes, and the
sensitivity of BM-FC was higher than that of PB-FC. In all
discordant cases (4.8%), monoclonal B lymphocytes were
present in the BM, whereas in PB the monoclonal cell
population was absent or under the sensitivity of the pro-
cedure. This was observed at diagnosis and after CT (p <
0.001 in both cases). In discordant cases, BM monoclonal
B-cells ranged from 0.06% to 18% of all leucocytes.
Among the 96 discordant cases, the most frequent diagno-
sis was Waldenstrom’s macroglobulinemia (WM) (20.8%).
Sixty-two percent of discordant samples were collected
after chemotherapy, and in discordant samples the most
frequent treatment (38.5% of all discordant cases) was
Rituximab alone or in association with chemotherapy.
Concordance between BM-TB and BM-FC
Results of BM-TB are reported in Table 3. The concor-
dance between BM-FC and BM-TB was 84% (83% at
diagnosis and 85% after treatment). This result is in line
with previous studies dealing with smaller series of
patients that showed a 79-90% concordance [9].
Among discordant cases (16%, 135 samples, Figure 2),
75% of the samples (101 samples) were BM-FCpos/BM-
TBneg and 25% (34 samples) were BM-FCneg/BM-
TBpos. Among BM-FCpos samples, 30% (30 samples)
were evaluated at first diagnosis (vs 36%, 12 samples, of
BM-TPpos cases at first diagnosis, p = 0.79) and 70%
(71 samples) were evaluated after therapy (vs 64%, 22
samples, of BM-TBpos cases after therapy, p = 0.89).
Figure 1 A-D: Representative FC dot plots showing the sequential multiparametric detection of clonal restriction in B-Lymphocytes
from a patient with follicular NHL. Panel A shows the gate made on lymphocytes; Panel B shows CD19 and CD45 expression in the
lymphocyte gate; Panel C shows the expression of CD5 and CD10; Panel D shows lambda chain clonal restriction; Panel E shows representative
CXCR4 expression in patients with follicular LNH and WM.
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In BM-FCpos/BM-TBneg samples, the percentage of
monoclonal B cells detected by FC was lower than 1%
of all leukocytes, while in BM-FCneg/BM-TBpos sam-
ples, the most frequent finding was the presence of a
nodular infiltrate. Differences in the frequency of posi-
tivity in the BM investigated by FC or TB were generally
not significant, with the exceptions of MZL-MALT after
therapy (38.6% by FC vs 23% by TB, p = 0.036), and
WM after therapy (40.4% by FC vs 74% by TB, p <
0.001). The difference observed in MCL at diagnosis
was of borderline significance (91.7% by FC vs 58% by
TB, p = 0.053). At diagnosis, BM-TBneg/BM-FCpos
cases were 0, 8, 33, 6, 8, and 0% in FL, DLBC, MCL,
MZL-MALT, CLL and WM, respectively. After CT,
BM-TBneg/BM-FCpos cases were 0, 14, 0, 15, 4, and 0%
in FL, DLBC, MCL, MZL-MALT, CLL and WM,
respectively.
CXCR4 expression in different NHL subtypes
In WM, we observed a significant CXCR4 down-
regulation in comparison to other NHL types (Figure
1). Median MFI ratio was 6 in WM vs 15, 10 and 34
in DLBC-L, FL and CLL, respectively (p < 0.01).
CXR4 expression in B lymphocytes in the BM and in
the PB was not significantly different (data not shown).
Table 2 Concordance between BM-FC and PB-FC
Pts Samples BM+PB+ BM+PB- BM-PB+ BM-PB-
N° % N° % N° % N° % N° N° %
FL diag 250 13% 78 31,2% 12 4,8% 0 160 64,0%
after CT 454 23% 68 15,0% 14 3,1% 0 372 81,9%
both 205 35% 704 35% 146 20,7% 26 3,7% 0 532 75,6%
DLBC diag 146 7% 22 15,1% 10 6,8% 0 114 78,1%
after CT 218 11% 56 25,7% 4 1,8% 0 158 72,5%
both 142 24% 364 18% 78 21,4% 14 3,8% 0 272 74,7%
MCL diag 24 1% 21 87,5% 1 4,2% 0 2 8,3%
after CT 198 10% 69 34,2% 1 0,5% 0 128 63,4%
both 47 8% 222 11% 90 39,8% 2 0,9% 0 130 57,5%
MZL-MALT diag 74 4% 26 35,1% 3 4,1% 0 45 60,8%
after CT 154 8% 56 37,3% 2 1,3% 0 96 64,0%
both 74 13% 228 11% 82 36,6% 5 2,2% 0 141 62,9%
CLL diag 78 4% 74 94,9% 0 0,0% 0 4 5,1%
after CT 236 12% 152 64,4% 14 5,9% 0 70 29,7%
both 83 14% 314 16% 226 72,0% 14 4,5% 0 74 23,6%
WM diag 44 2% 23 52,3% 10 22,7% 0 11 25,0%
after CT 124 6% 25 20,2% 25 20,2% 0 74 59,7%
both 40 7% 168 8% 48 28,6% 35 20,8% 0 85 50,6%
TOTAL 591 100% 2000 100% 670 33,5% 96 4,8% 0 1234 61,7%
Table 3 BM-TB results
Samples BM+ BM-
N° % N° % N° %
FL diag 96 31% 32 42% 64 28%
after CT 212 69% 44 58% 168 72%
both 308 36% 76 25% 232 75%
DLBC diag 68 41% 9 13% 59 87%
after CT 99 59% 12 12% 87 88%
both 167 20% 21 13% 146 87%
MCL diag 12 13% 7 58% 5 42%
after CT 78 87% 28 36% 50 64%
both 90 11% 35 39% 55 61%
MZL-MALT diag 33 32% 11 33% 22 67%
after CT 69 68% 16 23% 53 77%
both 102 12% 27 26% 75 74%
CLL diag 23 20% 20 87% 3 13%
after CT 90 80% 59 66% 31 34%
both 113 13% 79 70% 34 30%
WM diag 15 25% 13 87% 2 13%
after CT 46 75% 34 74% 12 26%
both 61 7% 47 77% 14 23%
TOTAL 841 100% 285 34% 556 66%
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The crucial role of CXCR4 in WM cell homing in the
marrow has been recently described [10]. Our current
results suggest that CXCR4 expression is variable among
different NHL subtypes, and lead to speculate a CXCR4
involvement in NHL blood spreading, possibly explaining
the discordant results of BM and PB analyses in WM ver-
sus other NHL types. In fact, a lower CXCR4 MFI ratio
was found in diseases where the presence of circulating
neoplastic B cells is less frequent (WM and DLBC), and a
higher ratio was found in NHL types associated with the
presence of circulating neoplastic B cells in a larger fre-
quency of cases (FL and CLL). Further studies are now
needed to validate this hypothesis.
Discussion
BM examination by BM-TB is an integral part of the clini-
cal staging and follow up of NHL patients. Along with
BM-TB, BM-FC is used as an ancillary investigation, even
though its use is still debated. The correlation between
these two techniques was found to be very high, and our
results are in line with previous studies dealing with smal-
ler series of patients (85% vs 80%-90%, see ref. [9]).
However, as BM aspiration might be a painful proce-
dure for patients, we retrospectively analyzed 1,000
paired BM aspirates and PB samples from NHL patients
to assess if PB analysis could be an alternative reliable
procedure for staging and follow up of these patients.
The overall FC concordance between BM and PB was
95.2%. Among the discordant cases, 62% of samples
were collected after chemotherapy and the most fre-
quent treatment was Rituximab alone or in association
with chemotherapy. This result suggests that during
treatment with Rituximab alone or in association with
chemotherapy, neoplastic B cells may be depleted in the
PB but still present in the BM. Therefore, a negative PB
sample obtained during treatment with Rituximab
should be considered with caution [8].
Among discordant cases, the most frequent diagnosis
was WM (20.8%). Among the different biological reasons
that might explain this discrepancy, we focused on
CXCR4. The crucial role of CXCR4 in WM cell homing in
the BM has been recently described [10] and our results,
even though obtained in a small number of patients and
samples, confirm this hypothesis. In fact, CXCR4 expres-
sion on B lymphocytes was found to be down-regulated
when compared to other NHL types (p < 0.001).
Albeit the investigation of NHL patients’ clinical out-
come was beyond the scope of the present study,
encompassing a large variety of NHL types and treat-
ment plans, we tried to investigate the clinical outcome
of the discordant cases. However, the clinical follow-up
of the discordant cases did not offer any meaningful and
significant information, because of the very large variety
of different treatment procedures in the patients.
To the best of our knowledge, only two previous
papers have reported about the role of FC in clinical
NHL outcome. Perea et al [9] reported discordance
between BM-FC and BM-TB (BM-FCpos/BM-TBneg) in
9% (36) of low-grade NHL patients, in most cases (66%)
affected by FL. In this study, discordance had no appar-
ent influence on the clinical outcome when compared
with BM-negative patients (median follow-up 14
months). In the second study, Gronich et al [11] investi-
gated 70 low-grade NHL patients and reported that the
outcome in patients who had BM involvement defined
by FC alone or by morphology was similar.
Conclusions
Our data indicate that - WM excluded - FC investiga-
tion of BM and PB in NHL patients gives overlapping
Figure 2 Analysis of discordance between BM-FC and BM-TB.
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information. This finding might have major implications
for the design of future NHL clinical studies and suggest
that the FC investigation of PB has potential as a possi-
ble alternative to BM-TB for the follow-up of NHL
patients.
Acknowledgements
Supported in part by AIRC (Associazione Italiana per la Ricerca sul Cancro),
and ISS (Istituto Superiore di Sanità).
Author details
1Laboratory of Hematology-Oncology, European Institute of Oncology, via
Ripamonti 435, 20141 Milan, Italy. 2Division of Pathology-Laboratory
Medicine, European Institute of Oncology, via Ripamonti 435, 20141 Milan,
Italy.
Authors’ contributions
PM, GP, and FB: designed the research, analyzed the data, and wrote the
paper.
AC, PA, JQ performed flow cytometric analysis, and analyzed the data. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 May 2010 Accepted: 24 November 2010
Published: 24 November 2010
References
1. Yan Y, Chan WC, Weisenburger DD, Anderson JR, Bast MA, Vose JM,
Bierman PJ, Armitage JO: Clinical and prognostic significance of bone
marrow involvement in patients with diffuse aggressive B-cell
lymphoma. Journal of Clinical Oncology 1995, 13:1336-1342.
2. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ,
Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S,
Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM,
Federico M, Diehl V: Revised response criteria for malignant lymphoma.
Journal of Clinical Oncology 2007, 25:579-586.
3. Laurence AD: Location, movement and survival: the role of chemokines
in haematopoiesis and malignancy. British Journal of Haematology 2006,
132:255-267.
4. Bertolini F, Dell’Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S,
Gobbi A, Pruneri G, Martinelli G: CXCR4-neutralization, a novel therapeutic
approach for non-Hodgkin lymphoma. Cancer Research 2002,
62:3106-3112.
5. Harris NH, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J,
Lister TA, Bloomfileld CD: World Health Organization Classification of
neoplastic diseases of the hematopoietic and lymphoid tissues: Report
of the clinical advisory committee meeting - Airlie House, Virginia,
November 1997. Journal of Clinical Oncology 1999, 17:3835-3849.
6. Sánchez ML, Almeida J, Vidriales B, López-Berges MC, García-Marcos MA,
Moro MJ, Corrales A, Calmuntia MJ, San Miguel JF, Orfao A: Incidence of
phenotypic aberrations in a series of 467 patients with B chronic
lymphoproliferative disorders: basis for the design of specific four-color
stainings to be used for minimal residual disease investigation. Leukemia
2002, 16:1460-1469.
7. Hanson CA, Kurtin PJ, Jerry A, Katzmann JA, Hoyer JD, Li CY, Hodnefield JM,
Meyers CH, Habermann TM, Witzig TE: Immunophenotypic Analysis of
Peripheral Blood and Bone Marrow in the Staging of B-Cell Malignant
Lymphoma. Blood 1999, 94:3889-3896.
8. Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL,
Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y,
Coltre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M,
Byrd JC, Hallek MJ, Montserrat E, Hillmen P: International standardized
approach for flow cytometric residual disease monitoring in chronic
lymphocytic leukaemia. Leukemia 2007, 21:956-964.
9. Perea G, Altes A, Bellido M, Aventin A, Bordes R, Ayats R, Remacha AF,
Espinosa I, Briones J, Sierra J, Nomdedeu JF: Clinical utility of bone marrow
flow cytometry in B-cell non-Hodgkin lymphomas. Histopathology 2004,
45:268-274.
10. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N,
Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM:
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom
macroglobulinemia. Blood 2008, 112:150-158.
11. Gronich N, Radnay J, Shapiro H, Manor Y, Lahav M, Lishner M: Clinical
outcome of low-grade NHL patients with bone marrow involvement.
European Journal of Clinical Investigation 2007, 37:05-309.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/644/prepub
doi:10.1186/1471-2407-10-644
Cite this article as: Mancuso et al.: If it is in the marrow, is it also in the
blood? An analysis of 1,000 paired samples from patients with B-cell
non-Hodgkin lymphoma. BMC Cancer 2010 10:644.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mancuso et al. BMC Cancer 2010, 10:644
http://www.biomedcentral.com/1471-2407/10/644
Page 6 of 6
